Circulating biomarkers to monitor cancer progression and treatment
Tumor heterogeneity is a major challenge and the root cause of resistance to treatment. Still, the standard diagnostic approach relies on the analysis of a single tumor sample from a local or metastatic site that is obtained at a given time point. Due to intratumoral heterogeneity and selection of s...
Hlavní autoři: | Suthee Rapisuwon, Eveline E. Vietsch, Anton Wellstein |
---|---|
Médium: | Článek |
Jazyk: | English |
Vydáno: |
Elsevier
2016-01-01
|
Edice: | Computational and Structural Biotechnology Journal |
Témata: | |
On-line přístup: | http://www.sciencedirect.com/science/article/pii/S2001037016300113 |
Podobné jednotky
-
Circulating cell-free nucleic acids of plasma in human aging, healthy aging and longevity: current state of knowledge
Autor: Nicolas P. Tessier, a další
Vydáno: (2023-11-01) -
Circulating Cell-free Tumor Nucleic Acids in Gastric Cancer
Autor: Hyun-Ji Lee, a další
Vydáno: (2018-09-01) -
The Role of Circulating Biomarkers in Lung Cancer
Autor: Sayuri Herath, a další
Vydáno: (2022-01-01) -
Liquid biopsy in gallbladder carcinoma: Current evidence and future prospective
Autor: Sridhar Mishra, a další
Vydáno: (2024-12-01) -
Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Autor: Pablo J. Dopico, a další
Vydáno: (2022-03-01)